NASDAQ:AMGN
Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 14 opinions in the last 12 months.
Amgen Inc. (AMGN) is viewed as a solid investment opportunity within the biopharmaceutical sector due to its diversification, consistent earnings, and growth potential. The company is trading at a relatively low price-to-earnings ratio compared to peers like Eli Lilly (LLY), making it appealing for investors seeking value. Despite some concerns around its weight-loss drug's recent performance, there is optimism about its potential market impact, with estimates of billions in additional revenue. The company's recent acquisition of Horizon Therapeutics is expected to enhance growth prospects, while its legacy products continue to perform well. Overall, experts highlight Amgen as a core holding with potential for dividend growth and capital appreciation.
AMGN is a large, safe, blue chip healthcare company trading at a low valuation of 13X earnings, with a 3.29% dividend that has shown growth. Cash flow is high and stable and the company has shown good historical earnings growth. Cons are that earnings growth is slowing, the sector is vulnerable to possibly-negative government changes (price controls) and lots of competition on some of its newer products. We would like to see a better future pipeline of products. Amgen's reliance on legacy drugs, like Prolia, and biosimilars to drive growth is likely to create an overhang as these products lose exclusivity over the coming years. Its last quarter was decent, with results ahead of expectations. We would consider it a decent, safe buy in the healthcare sector.
Unlock Premium - Try 5i Free
It's been tough in healthcare, but Amgen is good. They spent a few years ago $28 billion to buy Horizon Therapeutics to deepen their bench in biotech, including blood cancer drugs. Trades at a low multiple and pays over a 3% dividend. Plus they have a potential GLP-1 drug.
Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q
In the last year, 3 stock analysts published opinions about AMGN-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..
Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.
On 2025-06-27, Amgen Inc. (AMGN-Q) stock closed at a price of $277.13.
Is working on its injectable GLP-1 drug, Maritide. The market didn't like its drug data (phase 2 clinical trials) last Monday, and sold shares hard: 20% avg. weight loss for obesity only, and 17% weight loss for obestity and diabetes. Also, Maritiude made users puke if they took high doses, though this is reduced if doses start small and then are increased. Still, the market was not impressed. Also, there exist 2 GLP-1 shots by competitors already. Thirdly, American prefer taking a pill daily (Eli Lilly) than an injection weekly (Amgen). He feels that the market misunderstood the trial results, and does not justify the stock's decline. LLY remains his favourite in GLP-1, but Amgen stock is cheap.